1. Home
  2. ASBP vs LSTA Comparison

ASBP vs LSTA Comparison

Compare ASBP & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aspire Biopharma Holdings Inc.

ASBP

Aspire Biopharma Holdings Inc.

HOLD

Current Price

$0.10

Market Cap

15.0M

Sector

Health Care

ML Signal

HOLD

Logo Lisata Therapeutics Inc.

LSTA

Lisata Therapeutics Inc.

HOLD

Current Price

$2.08

Market Cap

16.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASBP
LSTA
Founded
2021
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Misc Health and Biotechnology Services
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.0M
16.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ASBP
LSTA
Price
$0.10
$2.08
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$23.50
AVG Volume (30 Days)
42.7M
33.4K
Earning Date
02-24-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,941.00
$1,070,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.07
$1.81
52 Week High
$15.80
$4.11

Technical Indicators

Market Signals
Indicator
ASBP
LSTA
Relative Strength Index (RSI) 44.10 52.38
Support Level $0.10 $1.84
Resistance Level $0.17 $2.12
Average True Range (ATR) 0.02 0.13
MACD 0.00 0.02
Stochastic Oscillator 13.83 66.67

Price Performance

Historical Comparison
ASBP
LSTA

About ASBP Aspire Biopharma Holdings Inc.

Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.

About LSTA Lisata Therapeutics Inc.

Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.

Share on Social Networks: